Norethynodrel

A synthetic progestational hormone with actions and uses similar to those of progesterone. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with mestranol.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Norethynodrel is 298.40.
Contraindications
Norethynodrel is contraindicated in conditions like Thrombosis,Vaginal bleeding,Amenorrhoea.
Effects
The severe or irreversible adverse effects of Norethynodrel, which give rise to further complications include Thromboembolism, Hirsutism.The signs and symptoms that are produced after the acute overdosage of Norethynodrel include Diarrhea, Jaundice, Headache, Insomnia, Pain, Pre-menstrual syndrom.The symptomatic adverse reactions produced by Norethynodrel are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Weight gain, Gynecomastia, GI disturbance, Mental depression.
Indications
Norethynodrel is primarily indicated in conditions like Abnormal uterine bleeding, Contraception, Endometriosis, Menstruation disorders.
Interactions
No data regarding the interactions of Norethynodrel was found.
Interfrence
Abnormal LFTs
Risks
Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Norethynodrel should be used with caution in patients with cardiovascular or renal impairment, diabetes mellitus, asthma, epilepsy, and migraine, or other conditions which may be aggravated by fluid retention. They should also be used with care in persons with a history of depression. High doses should be used with caution in patients susceptible to thromboembolism. Norethynodrel should not be given to patients with undiagnosed vaginal bleeding, nor to those with a history or current high risk of arterial disease and should generally be avoided in hepatic impairment, especially if severe. Unless Norethynodrel are being used as part of the management of breast or genital-tract carcinoma they should not be given to patients with these conditions.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.